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Use of high ultrafiltrate flow rates with continuous venovenous hemofiltration (CVVHF) in critically ill
patients is an emerging setting, for which there are few data to guide drug dosing. The objectives of this study
were, firstly, to investigate the pharmacokinetics of meropenem in critically ill patients with severe sepsis who
are receiving high-volume CVVHF with high-volume exchanges (>4 liters/h); secondly, to determine whether
standard dosing regimens (1,000 mg intravenously [i.v.] every 8 h) are sufficient for treatment of less
susceptible organisms such as Burkholderia pseudomallei (MIC, 4 mg/liter); and, finally, to compare the
clearances observed in this study with data from previous studies using lower-volume exchanges (1 to 2
liters/h). We recruited 10 eligible patients and collected serial pre- and postfilter blood samples and ultrafil-
trate and urine samples. A noncompartmental method was used to determine meropenem pharmacokinetics.
The cohort had a median age of 56.6 years, a median weight of 70 kg, and a median APACHE II (acute
physiology and chronic health evaluation) score of 25. The median (interquartile range) values for meropenem
were as follows: terminal elimination half-life, 4.3 h (2.9 to 6.0); terminal volume of distribution, 0.2 liters/kg
(0.2 to 0.3); trough concentration, 7.7 mg/liter (6.2 to 12.9); total clearance, 6.0 liters/h (5.2 to 6.2); hemofil-
tration clearance, 3.5 liters/h (3.4 to 3.9). In comparing the meropenem clearance here with those in previous
studies, ultrafiltration flow rate was found to be the parameter that accounted for the differences in clearance
of meropenem (R2  0.89). In conclusion, high-volume CVVHF causes significant clearance of meropenem,
necessitating steady-state doses of 1,000 mg every 8 h to maintain sufficient concentrations to treat less
susceptible organisms such as B. pseudomallei.
Sepsis is a leading cause of morbidity and mortality among
critically ill patients (8), and the mainstay of treatment is early
initiation of broad-spectrum antibiotics and advanced support-
ive care. Acute kidney injury (AKI) occurs in up to 5% of all
critically ill patients, and 70% of these patients will require
renal replacement therapy (RRT) (16). An ongoing concern
for these patients is the persisting high mortality rates that
have been reported to be as high as 60% (24). Optimized
antibiotic dosing may help reduce this burden. However, de-
spite our knowledge of the significant problems associated with
the presence of infection in critically ill patients, there is a
paucity of data to guide antibiotic dosing with differing RRT
settings and modalities.
Meropenem is an antibiotic that is often used for empirical
treatment of infections in critically ill patients with AKI (10). It
has clinically insignificant protein binding (2 to 3%) (10) and,
as a carbapenem antibiotic, shows time-dependent bacterial
killing, meaning that the unbound or free (f) antibiotic con-
centration in blood should be maintained above the MIC of
the pathogen for at least 40% of the dosing interval (f 40%
TMIC) (7). Emerging retrospective human data suggest that
clinical advantages may exist for maintaining meropenem con-
centrations for longer periods and at concentrations up to five
times the MIC (f 100% T5MIC) (1, 17). While the elimina-
tion half-life of meropenem is increased in patients with renal
dysfunction, the addition of RRT will cause some level of
meropenem clearance (6, 9, 14, 23, 26). Therefore, dosing
strategies specific for critically ill patients receiving RRT are
essential to optimize antibiotic exposure and minimize the
poor clinical outcomes observed in these patients (19).
The pharmacokinetics of meropenem have been described
in patients being treated with continuous venovenous hemo-
filtration (CVVHF), continuous venovenous hemodialysis
(CVVHD), and continuous venovenous hemodiafiltration
(CVVHDF) (4, 9, 11, 13–15, 21–23, 25, 26). There is signif-
icant variability in the pharmacokinetics of meropenem in
these studies. RRT clearance of meropenem is thought to be
related to the volume of ultrafiltrate, the surface area of the
filter membrane, the blood flow, and the duration of renal
replacement therapy (RRT) (14). Previous studies have used
filter membrane surface areas ranging from 0.45 to 0.9 m2, and
fluid exchanges used between 1 and 2 liters/h. The recom-
mended meropenem dosing regimens arising from these stud-
ies have ranged between 500 mg every 12 hours and 1,000 mg
every 12 hours, which were reported to provide therapeutic
concentrations to treat susceptible pathogens with a mero-
penem MIC90 of 0.1 to 0.2 mg/liter.
Despite these detailed studies, there are no data to describe
the pharmacokinetics of meropenem during high-volume
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CVVHF. High-volume CVVHF uses high-volume exchanges and
filters with larger membrane surface areas. This modality of
CVVHF is reported to provide more rapid clearance of in-
flammatory mediators and stabilization of physiologic param-
eters. Furthermore, there is some evidence that high-volume
filtration may be of clinical benefit in patients with severe
sepsis (3).
However, treatment of more-resistant bacteria, such as
Burkholderia pseudomallei (MIC90, 4 mg/liter) and some strains
of Pseudomonas aeruginosa, is problematic. B. pseudomallei is a
significant part of the sepsis burden in tropical Australia. It is
an intracellular, Gram-negative bacterium causing melioidosis,
a community-acquired infection with high mortality rates (5,
12). For this serious infection, meropenem is the optimal an-
tibiotic choice (5).
The objectives of this study were, first, to investigate the
pharmacokinetics of meropenem in critically ill patients with
severe sepsis who are receiving high-volume CVVHF with
high-volume exchanges (4 liters/h); second, to determine
whether standard dosing regimens are sufficient for treatment
of less susceptible organisms such as B. pseudomallei; and,
finally, to compare the clearances observed in this study with
data from previous studies using lower-volume exchanges (1 to
2 liters/h).
(This study was presented, in part, at the 2009 Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA.)
MATERIALS AND METHODS
This was a prospective, observational pharmacokinetic trial, performed in the
intensive care unit of a 350-bed teaching hospital in Australia. The study was
approved by the Human Research Ethics Committees of the Northern Territory
Department of Health and Families and Menzies School of Health Research
(ethics approval 08/37, 16 July 2008).
Patient selection and data collection. Patients who met the American College
of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) criteria for
sepsis (2) and were receiving high-volume CVVHF for oligo- or anuric-renal
failure were eligible for enrollment. Meropenem was prescribed at the discretion
of the treating intensive care physician. Informed consent was obtained from the
patient or the patient’s legally authorized representative.
Meropenem administration. All patients were administered a standard dose of
meropenem, 1,000 mg, via central venous catheter every 8 hours in line with local
departmental guidelines. Meropenem was reconstituted with 20 ml of sterile
water for injection and given as a bolus.
Renal replacement therapy. Continuous venovenous hemofiltration (CVVHF)
was performed in all the patients using the Nephral ST500 (AN69 hollow-fiber)
filter with a surface area of 2.15 m2. All patients were initiated on the CVVHF
at least 8 hours prior to the sampling period. Vascular access was obtained via
the subclavian, internal jugular, or femoral vein, using a double-lumen 10G 14Fr
catheter. The ultrafiltrate rate was set between 4 and 6 liters/h, with a target
blood flow rate of 15 liters/h. The circuit was anticoagulated with heparin or
citrate at the physician’s discretion.
Sample collection. Pharmacokinetic sampling occurred during one 8-hour
dosage interval at steady state (defined as after the fourth meropenem dose). To
minimize interruptions from filter failure from clotting, the filter was changed if
it was more than 3 h old at the commencement of the sampling period. Two
milliliters of blood was collected in a lithium heparin tube pre- and postfilter,
predose, and at 15, 30, 45, 60, 120, 240, and 480 min. Ultrafiltrate samples were
collected at the same time points. Total ultrafiltrate and urine for the dosing
period were measured, and 10-ml aliquots were kept for analysis. All samples
were immediately refrigerated at 4°C, and plasma was separated and frozen at
80°C within 24 h of sample collection. The blood samples were centrifuged at
3,000 rpm for 10 min.
Meropenem assay. Meropenem concentrations in plasma, ultrafiltrate, and
urine were determined by validated assay methods on a Shimadzu Prominence
high-pressure liquid chromatography (HPLC) system. The stationary phase was
a Phenomenex Gemini C18 column (5 m, 150  3 mm), and the mobile phase
was acetonitrile with 10 mM phosphate buffer at pH 6.5 (10%:90% organic
agent/buffer). Meropenem and the internal standard (ertapenem) were detected
by UV detection at 298 nm.
Meropenem standards and quality controls were prepared in matrices of
plasma, ultrafiltrate, and urine. For all three matrices 100 l of sample was
diluted with buffer at pH 6.5 and internal standard, while plasma samples were
subsequently deproteinated with acetonitrile and washed with dichloromethane
before injection. Linearity was validated from 1 to 500 g/ml (plasma), 1 to 200
g/ml (ultrafiltrate), and 10 to 1,000 g/ml (urine; dilution for samples over 1,000
g/ml was validated at within 2%). Accuracy and precision were determined
from n  6 replicates of quality controls at high, medium, and low concentra-
tions; results were within 6% for all matrices at all levels.
Pharmacokinetic analysis. The pharmacokinetic values were calculated using
noncompartmental methods. The area under the concentration-time curve from
0 to 8 h (AUC0–8) was calculated using the linear trapezoidal rule. Total body
clearance (CLtot) was calculated as dose/AUC0–8. The area under the moment
curve (AUMC0–8) was calculated using the linear trapezoidal rule. Mean resi-
dence time (MRT) was calculated as AUMC0–8/AUC0–8. The maximum concen-
tration for the dosing period (Cmax) and the minimum concentration for the
dosing period (Cmin) were the observed values; the apparent terminal elimina-
tion rate constant (z) was determined from log-linear least squares regression
analysis of concentrations from 2 to 8 h; the apparent volume of distribution
during terminal phase (Vz) was CL/z; the half-life (t1/2) was ln(2)/z. The ex-
traction ratio (ER) across the filter was calculated as the ratio of the meropenem
venous blood sample concentration to the arterial blood sample concentration,
and the sieving coefficient (SC) was calculated as the ratio of the concentration
of meropenem in the ultrafiltrate to the concentration in the arterial blood
TABLE 1. Clinical and demographic characteristics of patientsa
Patient Age (yr) Gender Wt (kg) INR Albumin Diagnosis
APACHE
II score
(admission)
Clinical
outcome
1 71 Male 95 1.4 22 Septic shock; source unknown 25 Death
2 48 Female 50 1.1 25 Pneumonia and septic shock 18 Home
3 56 Male 70 1.6 26 Pneumonia and septic shock 32 Death
4 61 Male 105 0.8 41 Pneumonia and septic shock 22 Death
5 45 Female 70 1.1 31 Biliary sepsis and septic shock 27 Home
6 57 Male 110 1.3 28 Septic arthritis and septic shock 29 Transferred
7 51 Female 60 1.0 21 Skin abscess and septic shock 30 Home
8 69 Male 110 1.4 20 Cellulitis and septic shock 18 Home
9 59 Male 70 1.1 27 Peritonitis and septic shock 25 Home
10 29 Female 65 1.2 29 Urinary sepsis and septic shock 22 Home
Median 57 70 25
25th percentile 49 66 22
75th percentile 61 103 28
a Abbreviations: INR, international normalized ratio; APACHE, acute physiology and chronic health evaluation.
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sample. Renal clearance (CLrenal) was calculated using the equation CLrenal 
Aurine0-8/AUC0–8 where Aurine0-8 is the total amount of meropenem recovered
in the urine from 0 to 8 h. Clearance by CVVHF (CLCVVHF) was calculated
using the equation CLCVVHF  ACVVHF/AUCCVVHF0-8 where ACVVHF is the
total amount of meropenem recovered in the ultrafiltrate from 0 to 8 h and
AUCCVVHF0-8 is the area under the concentration-time curve in CVVHF
from 0 to 8 h. Clearance not mediated by CVVHF (CLnon-CVVHF) was
calculated using the equation CLnon-CVVHF  CLtot  CLCVVHF.
Statistical analysis. Statistical analyses were performed using Prism (Graph-
Pad, version 4.03; San Diego, CA) and Microsoft Excel (Microsoft Office 2007;
Redmond, WA). Correlations between factors were determined using linear
regression.
RESULTS
Clinical data. Ten patients were enrolled in the study. The
clinical and demographic characteristics of the patients are
described in Table 1. The plasma pharmacokinetic data are
described in Table 2. Figure 1 shows the median (interquartile
range) plasma meropenem concentrations over one dosing in-
terval in the 10 patients. The hemofiltration settings and phar-
macokinetic data are described in Table 3.
We omitted the 8-h sample from patients 4, 5, and 6 from
analysis as we observed values more than 4 standard deviations
outside the likely value. The likely reason for the unexplained
values was inadvertent early administration of the subsequent
dose. In the absence of the actual 8-hour sample for these
patients, we used the trough concentration from the previous
dose as a surrogate concentration in the pharmacokinetic anal-
yses. To confirm the appropriateness of this assumption, we
determined an elimination rate constant using linear regres-
sion from the 2-h and 4-h samples to confirm that the previous
trough concentration was appropriate given the rate of clear-
ance observed in the present dosing interval.
Previous studies have been published describing the phar-
macokinetics of meropenem in various forms of CVVHF with
low-volume exchanges. The settings and pharmacokinetics pa-
rameters observed in these studies are compared with those
observed in this study in Table 4. When attempting to explain
the different CVVHF clearances that have been reported by
these previous studies, only ultrafiltrate flow rate (UFR) en-
abled normalization of data for drug clearance (R2  0.89).
Neither membrane surface area (R2  0.30) nor blood flow
rate (R2  0.18) could sufficiently describe meropenem hemo-
filtration clearance. No other demographic, clinical, or dialysis
factors were found to describe meropenem CVVHF clearance
adequately.
DISCUSSION
This is the first study to investigate the pharmacokinetics of
meropenem during high-volume CVVHF. The results of this
study show significant meropenem clearance in patients with
acute kidney injury receiving CVVHF with high-volume ex-
changes.
Meropenem is a frequently used empirical antibiotic treat-
ment in the critical care setting because of its broad spectrum
of action. Pharmacodynamically, meropenem shows time-de-
pendent bacterial killing, and optimal bactericidal activity sug-
gests that maintaining a concentration above the MIC for at
least 40% of the dosing time is required. However, emerging
retrospective clinical studies involving meropenem support a
longer f TMIC in critically ill patients of up to 100% of the
dosing interval (18, 19). However, for critically ill patients with
renal dysfunction or those requiring renal replacement therapy
such as CVVHF, there remains significant concern from clini-
FIG. 1. Median (and interquartile) concentration-versus-time data
for the enrolled patients. The black broken line represents the MIC for
B. pseudomallei (4 mg/liter).
TABLE 2. Pharmacokinetic parameters from plasma dataa
Patient Cmax(mg/liter)
Cmin
(mg/liter)
AUC0-8
(mg  h/liter)
AUMC0-8
(mg  h2/liter) MRT (h)
CLtot
(liters/h)
CLrenal
(liters/h)
CLnon-CVVHF
(liters/h) Kel (h
1) t1/2 (h)
Vz
(liters/kg)
1 50.4 14.3 169.1 31,538.3 186.5 5.9 0.007 2.0 0.11 6.53 0.21
2 58.3 5.70 139.8 20,905.9 149.6 7.2 0.003 3.2 0.26 2.72 0.76
3 54.8 7.57 162.2 26,012.7 160.4 6.2 0.000 2.7 0.20 3.46 0.46
4 61.9 4.21 174.3 38,821.5 222.7 5.7 0.000 2.3 0.10 6.90 0.21
5 74.7 21.5 397.5 112,647.4 283.4 2.5 0.000 0.0 0.09 8.07 0.35
6 42.7 7.2 163.8 38,016.8 232.1 6.1 0.024 3.1 0.16 4.30 0.34
7 74.8 16.9 281.0 49,981.5 177.9 3.6 0.000 0.2 0.16 4.47 0.46
8 49.4 8.73 159.9 27,308.6 170.7 6.3 0.018 2.5 0.26 2.68 0.40
9 42.4 5.93 115.3 18,919.1 164.1 8.7 0.011 4.6 0.35 2.00 0.81
10 66.9 7.63 199.4 31,218.3 156.6 5.0 0.008 1.5 0.16 4.35 0.31
Median 56.6 7.6 166.5 31,378.3 174.3 6.0 0.005 2.4 0.16 4.32 0.37
25th percentile 49.7 6.2 160.5 26,336.7 161.3 5.2 0.000 1.6 0.12 2.90 0.32
75th percentile 65.7 12.9 193.1 38,620.3 213.7 6.2 0.010 3.0 0.24 6.02 0.46
a Abbreviations: Cmax, observed maximum concentration during sampling period; Cmin, observed minimum concentration during sampling period; AUC0-8, area
under the concentration-time curve during 8-hour dosing period; AUMC0-8, area under the moment curve during 8-hour dosing period; MRT, mean residence time;
CLtot, total clearance; CLrenal, renal clearance; CLnon-CVVHF, clearance not mediated by CVVHF; Kel, elimination rate constant; t1/2, elimination half-life; Vz, apparent
volume of distribution during terminal phase.
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cians that dosing recommendations facilitate optimal pharma-
codynamic exposures of meropenem.
The pharmacokinetics of meropenem in CVVHF have been
studied previously. However, the operational characteristics of
the CVVHF used in these studies have varied greatly; the
membrane surface areas have varied between 0.43 and 0.9 m2,
the ultrafiltrate flow rate (UFR) between 1 and 2 liters/h, and
the blood flow rates between 0.6 and 12 liters/h, and different
types of membranes have been used. The local protocol used at
our institution uses significantly higher blood flow rates (250
ml/min), higher UFRs (4.4 liters/h), and a membrane with a
surface area of 2.15 m2. Hence, our study is able to provide a
valuable contrast between each of the studies on the relative
effect of UFR on meropenem clearance.
In this study, we observed a median clearance due to this
form of hemofiltration of 3.49 liters/h. Compared to the pre-
vious studies using low ultrafiltrate flow rates, we have ob-
served that meropenem clearance is largely explained by the
differing UFRs. In evaluating the total clearance (CLtot) from
each of the studies, the reasons for the differences are not
apparent. The effects of residual renal function and the levels
of sickness severity were reported inconsistently between these
studies, making a systematic interpretation not possible.
Knowledge of drug clearance during a form of renal replace-
ment therapy is important. However, dosing can rarely be
based solely on clearance data. Once steady state has been
achieved, dosing should be based on drug clearance. In renally
impaired patients receiving renal replacement therapy, consid-
eration of possible residual renal clearance or other nonrenal
clearance is essential. Although data for upregulated nonrenal
clearance exist for ciprofloxacin in renal dysfunction (20), we
are not aware of any similar data for meropenem.
This paper has shown that meropenem clearance during
CVVHF is heavily influenced by UFR. It follows that the
clinical use of high-volume CVVHF requires a higher mero-
penem dose than previously considered necessary for CVVHF.
Our data suggest that CVVHF settings similar to that used in
our study require a steady-state meropenem dose of 1,000 mg
every 8 h to maintain concentrations above the MIC of less
susceptible pathogens such as B. pseudomallei (MIC90, 4.0 mg/
TABLE 3. Hemofiltration settings and pharmacokinetic dataa
Patient Filterage (min)
Mean
blood flow
(liters/h)
Mean
UFR
(liters/h)
Urine vol
(0-8 h)
(liters)
AUC0-8
(mg  h/liters)
AUMC0-8
(mg  h2/liters) MRT (h)
Extraction
ratio
CLCVVHF
(liters/h)
1 30 12.7 4.7 0.06 109.1 13,762.5 126.1 0.71 3.9
2 15 18.0 6.0 0.03 126.0 18,542.6 147.2 0.80 4.0
3 80 17.4 4.6 0.00 155.5 25,563.3 164.4 0.77 3.5
4 5 16.9 3.8 0.00 130.6 27,856.1 213.4 0.71 3.4
5 5 13.8 3.8 0.00 292.3 79,766.3 272.9 0.75 2.7
6 7 16.8 4.4 0.19 128.5 30,265.1 235.6 0.71 3.0
7 10 14.4 3.9 0.00 218.3 38,325.4 175.6 0.74 3.4
8 25 17.4 4.6 0.14 112.8 18,303.7 162.2 0.70 3.8
9 5 21.0 4.0 0.09 118.7 18,439.9 155.3 0.81 4.1
10 60 16.8 4.5 0.06 175.8 28,025.3 159.4 0.73 3.5
Median 24 16.5 4.4 0.08 129.5 26,709.7 163.3 0.74 3.5
25th percentile 5 15.0 3.9 0.04 120.5 18,465.6 156.4 0.71 3.4
75th percentile 29 17.4 4.6 0.114 170.7 29,705.2 203.9 0.77 3.9
a Abbreviations: UFR, ultrafiltrate flow rate; AUC0-8, area under the concentration-time curve during 8-hour dosing period; AUMC0-8, area under the moment curve
during 8-hour dosing period; MRT, mean residence time; CLCVVHF, hemofiltration clearance.
TABLE 4. Comparative operational settings and pharmacokinetic data from this study and previous studies of
meropenem clearance during CVVHFa
Study (reference) MembraneSA (m2)
BFR
(liters/h)
UFR
(liters/h) SC t1/2 (h)
V
(liters/kg)
CLCVVHF
(liters/h)
CLtot
(liters/h) CLCVVHF/SA CLCVVHF/BFR CLCVVHF/UFR
Thalhammer et
al., 1998 (23)
0.43 9 2.7 1.09 2.5 0.34 2.98 8.62 6.93 0.33 1.10
Tegeder et al.,
1999 (21)
0.9 10 1.1 1.17 8.7 0.19 1.32 3.10 1.47 0.13 1.20
Ververs et al.,
2000 (26)
0.9 12 1.6 0.63 6.3 0.37 0.96 4.57 1.07 0.08 0.60
Giles et al.,
2000 (9)
0.9 9 1.7 0.95 5.8 0.35 1.50 3.63 1.67 0.17 0.88
Valtonen et al.,
2000 (25)
0.7 6 0.4 NS 7.5 NS NS 3.27 NS NS NS
Krueger et al.,
2003 (13)
0.9 1 1.6 0.91 3.6 0.28 1.47 4.98 1.63 1.47 0.92
Bilgrami et al.,
2010
2.15 15 4.4 0.93 4.6 0.26 3.49 6.00 1.76 0.25 0.86
a Abbreviations: SA, surface area; BFR, blood flow rate; UFR, ultrafiltrate flow rate; SC, sieving coefficient; t1/2, elimination half-life; V, stated apparent volume of
distribution (V was at steady state in all studies except for references 23 and 25, which did not specify the value; in this study, the apparent V during terminal phase
was used); CLCVVHF, hemofiltration clearance; CLtot, total clearance; NS, data not stated.
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liter, compared with the median [90th percentile] trough con-
centration observed in this study of 7.6 mg/liter [5.5 mg/liter]).
For more susceptible organisms, a lower dose may be used,
although a lower dose would be inappropriate for empirical
therapy in most centers.
A possible limitation to the comparisons made between this
study and others using CVVHF with lower-volume exchanges
is the use of prefilter replacement fluid in this study. Of the
other studies undertaken, each of them used postfilter dilution
with replacement fluid. This is unlikely to affect the conclusions
on the importance of UFR for meropenem clearance but may
be important.
In conclusion, CVVHF with high-volume exchanges results
in significant clearance of meropenem. Comparing the results
of our study with previous studies that use lower-volume ex-
changes, we have been able to show that UFR is the main
determinant of meropenem clearance during CVVHF. It fol-
lows that, when using CVVHF with high-volume exchanges,
higher doses than those usually used in CVVHF are appropri-
ate. Our data suggest that steady-state dosing of 1,000 mg
every 8 h provides appropriate meropenem concentrations for
less susceptible organisms such as B. pseudomallei.
ACKNOWLEDGMENTS
We thank Kim Piera and Tonia Woodberry for the laboratory as-
sistance, the nursing and medical staff of the ICU, and the patients and
their relatives who agreed to be part of this study.
This study was funded by the National Health and Medical Research
Council of Australia (project grant 519702, fellowship to J. A. Roberts
and scholarship to J. Davis).
REFERENCES
1. Ariano, R. E., A. Nyhlen, J. P. Donnelly, D. S. Sitar, G. K. Harding, and
S. A. Zelenitsky. 2005. Pharmacokinetics and pharmacodynamics of
meropenem in febrile neutropenic patients with bacteremia. Ann. Phar-
macother. 39:32–38.
2. Bone, R. C., R. A. Balk, F. B. Cerra, R. P. Dellinger, A. M. Fein, W. A. Knaus,
R. M. Schein, and W. J. Sibbald. 1992. Definitions for sepsis and organ
failure and guidelines for the use of innovative therapies in sepsis. The
ACCP/SCCM Consensus Conference Committee. American College of
Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–1655.
3. Bouman, C. S., H. M. Oudemans-van Straaten, M. J. Schultz, and M. B.
Vroom. 2007. Hemofiltration in sepsis and systemic inflammatory response
syndrome: the role of dosing and timing. J. Crit. Care 22:1–12.
4. Bugge, J. F. 2001. Pharmacokinetics and drug dosing adjustments during
continuous venovenous hemofiltration or hemodiafiltration in critically ill
patients. Acta Anaesthesiol. Scand. 45:929–934.
5. Cheng, A. C., and B. J. Currie. 2005. Melioidosis: epidemiology, pathophys-
iology, and management. Clin. Microbiol. Rev. 18:383–416.
6. Chimata, M., M. Nagase, Y. Suzuki, M. Shimomura, and S. Kakuta. 1993.
Pharmacokinetics of meropenem in patients with various degrees of renal
function, including patients with end-stage renal disease. Antimicrob. Agents
Chemother. 37:229–233.
7. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions
of ‘bug and drug.’ Nat. Rev. Microbiol. 2:289–300.
8. Finfer, S., R. Bellomo, J. Lipman, C. French, G. Dobb, and J. Myburgh.
2004. Adult-population incidence of severe sepsis in Australian and New
Zealand intensive care units. Intensive Care Med. 30:589–596.
9. Giles, L. J., A. C. Jennings, A. H. Thomson, G. Creed, R. J. Beale, and A.
McLuckie. 2000. Pharmacokinetics of meropenem in intensive care unit
patients receiving continuous veno-venous hemofiltration or hemodiafiltra-
tion. Crit. Care Med. 28:632–637.
10. Hurst, M., and H. M. Lamb. 2000. Meropenem: a review of its use in patients
in intensive care. Drugs 59:653–680.
11. Isla, A., J. Maynar, J. A. Sanchez-Izquierdo, A. R. Gascon, A. Arzuaga, E.
Corral, and J. L. Pedraz. 2005. Meropenem and continuous renal replace-
ment therapy: in vitro permeability of 2 continuous renal replacement ther-
apy membranes and influence of patient renal function on the pharmacoki-
netics in critically ill patients. J. Clin. Pharmacol. 45:1294–1304.
12. Jenney, A. W., G. Lum, D. A. Fisher, and B. J. Currie. 2001. Antibiotic
susceptibility of Burkholderia pseudomallei from tropical northern Australia
and implications for therapy of melioidosis. Int. J. Antimicrob. Agents 17:
109–113.
13. Krueger, W. A., G. Neeser, H. Schuster, T. H. Schroeder, E. Hoffmann, A.
Heininger, H. J. Dieterich, H. Forst, and K. E. Unertl. 2003. Correlation of
meropenem plasma levels with pharmacodynamic requirements in critically
ill patients receiving continuous veno-venous hemofiltration. Chemotherapy
49:280–286.
14. Krueger, W. A., T. H. Schroeder, M. Hutchison, E. Hoffmann, H. J.
Dieterich, A. Heininger, C. Erley, A. Wehrle, and K. Unertl. 1998. Phar-
macokinetics of meropenem in critically ill patients with acute renal
failure treated by continuous hemodiafiltration. Antimicrob. Agents Che-
mother. 42:2421–2424.
15. Kuti, J. L., and D. P. Nicolau. 2005. Derivation of meropenem dosage in
patients receiving continuous veno-venous hemofiltration based on pharma-
codynamic target attainment. Chemotherapy 51:211–216.
16. Levy, E. M., C. M. Viscoli, and R. I. Horwitz. 1996. The effect of acute renal
failure on mortality. A cohort analysis. JAMA 275:1489–1494.
17. Li, C., X. Du, J. L. Kuti, and D. P. Nicolau. 2007. Clinical pharmacodynamics
of meropenem in patients with lower respiratory tract infections. Antimi-
crob. Agents Chemother. 51:1725–1730.
18. Roberts, J. A., and J. Lipman. 2009. Pharmacokinetic issues for antibiotics in
the critically ill patient. Crit. Care Med. 37:840–851.
19. Roberts, J. A., S. Webb, D. Paterson, K. M. Ho, and J. Lipman. 2009. A
systematic review on clinical benefits of continuous administration of beta-
lactam antibiotics. Crit. Care Med. 37:2071–2078.
20. Rohwedder, R., T. Bergan, S. B. Thorsteinsson, and H. Scholl. 1990. Transin-
testinal elimination of ciprofloxacin. Chemotherapy 36:77–84.
21. Tegeder, I., F. Neumann, F. Bremer, K. Brune, J. Lotsch, and G. Geisslinger.
1999. Pharmacokinetics of meropenem in critically ill patients with acute
renal failure undergoing continuous venovenous hemofiltration. Clin. Phar-
macol. Ther. 65:50–57.
22. Thalhammer, F., and W. H. Horl. 2000. Pharmacokinetics of meropenem in
patients with renal failure and patients receiving renal replacement therapy.
Clin. Pharmacokinet. 39:271–279.
23. Thalhammer, F., P. Schenk, H. Burgmann, I. El Menyawi, U. M. Hollen-
stein, A. R. Rosenkranz, G. Sunder-Plassmann, S. Breyer, and K. Ratheiser.
1998. Single-dose pharmacokinetics of meropenem during continuous veno-
venous hemofiltration. Antimicrob. Agents Chemother. 42:2417–2420.
24. Uchino, S., J. A. Kellum, R. Bellomo, G. S. Doig, H. Morimatsu, S. Morgera,
M. Schetz, I. Tan, C. Bouman, E. Macedo, N. Gibney, A. Tolwani, and C.
Ronco. 2005. Acute renal failure in critically ill patients: a multinational,
multicenter study. JAMA 294:813–818.
25. Valtonen, M., E. Tiula, J. T. Backman, and P. J. Neuvonen. 2000. Elimina-
tion of meropenem during continuous veno-venous haemofiltration and hae-
modiafiltration in patients with acute renal failure. J. Antimicrob. Che-
mother. 45:701–704.
26. Ververs, T. F., A. van Dijk, S. A. Vinks, P. J. Blankestijn, J. F. Savelkoul, J.
Meulenbelt, and F. T. Boereboom. 2000. Pharmacokinetics and dosing reg-
imen of meropenem in critically ill patients receiving continuous venovenous
hemofiltration. Crit. Care Med. 28:3412–3416.
2978 BILGRAMI ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 Septem
ber 3, 2013 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
